Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Aralez Pharmaceuticals Inc. (ARLZ) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/30/2020 GN Liquidia Corporation Appoints Michael Kaseta Chief Financial Officer
05/30/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "of the Bankruptcy of Old API Wind-down Ltd. of the City of Mississauga in the Province of Ontario To the"
05/13/2019 8-K Other Events
03/07/2019 8-K Quarterly results
02/06/2019 8-K Quarterly results
01/18/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/12/2018 8-K Entry into a Material Definitive Agreement
11/02/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Monthly Operating Report for the Period from September 1, 2018 to September 30, 2018"
10/05/2018 8-K Quarterly results
10/01/2018 8-K Quarterly results
09/27/2018 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
09/19/2018 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "NUVO PHARMACEUTICALS INC. as the Purchaser and ARALEZ PHARMACEUTICALS INC. as the Vendor and ARALEZ PHARMACEUTICALS CANADA INC. as the Corporation SHARE PURCHASE AGREEMENT",
"ASSET PURCHASE AGREEMENT by and among POZEN Inc., Aralez Pharmaceuticals Trading DAC and Nuvo Pharmaceuticals Limited Dated as of September 18, 2018",
"ASSET PURCHASE AGREEMENT by and between Aralez Pharmaceuticals Trading DAC, and Toprol Acquisition LLC Dated as of September 18, 2018",
"ARALEZ PHARMACEUTICALS ENTERS INTO DEFINITIVE “STALKING HORSE” PURCHASE AGREEMENTS FOR SUBSTANTIALLY ALL ASSETS"
08/14/2018 8-K Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation unde...
Docs: "SENIOR SECURED SUPER-PRIORITY DEBTOR-IN-POSSESSION CREDIT AGREEMENT AMONG ARALEZ PHARMACEUTICALS INC. AND",
"SENIOR SECURED SUPER-PRIORITY DEBTOR-IN-POSSESSION CREDIT AGREEMENT",
"ARALEZ PHARMACEUTICALS TO ENTER INTO PURCHASE AGREEMENTS TO SELL SUBSTANTIALLY ALL ASSETS"
07/26/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/29/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated 2016 Long-Term Incentive Plan"
06/29/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Amendment, by and between Aralez Pharmaceuticals, Inc., Aralez Pharmaceuticals Canada Inc., Pozen Inc., Deerfield Partners, L.P. and Deerfield Private Design Fund III, L.P"
06/26/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
06/06/2018 4 KOVEN ANDREW I (President & Chief Business Off) has filed a Form 4 on Aralez Pharmaceuticals Inc.
Txns: Sold 156,573 shares @ $0.3742, valued at $58.6k
06/06/2018 8-K Quarterly results
05/18/2018 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/18/2018 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/16/2018 4 KOVEN ANDREW I (President & Chief Business Off) has filed a Form 4 on Aralez Pharmaceuticals Inc.
Txns: Sold 13,964 shares @ $0.52, valued at $7.3k
05/16/2018 4 Tursi James Patrick (Chief Medical Officer) has filed a Form 4 on Aralez Pharmaceuticals Inc.
Txns: Sold 9,348 shares @ $0.5222, valued at $4.9k
05/08/2018 10-Q Quarterly Report for the period ended March 31, 2018
05/08/2018 8-K Quarterly results
Docs: "ARALEZ ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS",
"ARALEZ ANNOUNCES NEW STRATEGIC DIRECTION"
04/30/2018 10-K/A Annual Report for the period ended December 31, 2017 [amend]
04/25/2018 CT ORDER Form CT ORDER - Confidential treatment order:
04/05/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Modification of Contract, executed on April 3, 2018, between the United States of America and Aralez Pharmaceuticals US Inc"
03/26/2018 GN Eyenovia Appoints Three Industry Veterans to Board of Directors
03/21/2018 4 Tursi James Patrick (Chief Medical Officer) has filed a Form 4 on Aralez Pharmaceuticals Inc.
Txns: Sold 5,950 shares @ $1.7, valued at $10.1k
03/21/2018 4 Trachtenberg Eric (GC, CCO & Secretary) has filed a Form 4 on Aralez Pharmaceuticals Inc.
Txns: Sold 3,471 shares @ $1.7, valued at $5.9k
03/21/2018 4 KOVEN ANDREW I (President & Chief Business Off) has filed a Form 4 on Aralez Pharmaceuticals Inc.
Txns: Sold 9,739 shares @ $1.7, valued at $16.6k
03/21/2018 4 Glickman Mark A (Chief Commercial Officer) has filed a Form 4 on Aralez Pharmaceuticals Inc.
Txns: Sold 5,725 shares @ $1.7, valued at $9.7k
03/21/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy